NCT04320693
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Approved for marketing
Drug Category: Therapeutic Antibody
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes:
Exclusions:
https://ClinicalTrials.gov/show/NCT04320693